Novavax, Inc. and Serum Institute of India Pvt. Ltd. (SII) announced a regulatory submission to the South African Health Products Regulatory Agency (SAHPRA) for emergency use authorization (EUA) of Novavax’ recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M adjuvant. If authorized, the vaccine will be manufactured by and commercialized by SII in South Africa under the brand name Covovax.   The submission includes data from two pivotal Phase 3 clinical trials:...